Literature DB >> 16823932

Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?

Henry R Shinefield1.   

Abstract

Staphylococcus aureus is a ubiquitous bacterial species that causes serious disease in certain settings. S. aureus disease is difficult to treat, and antibiotic-resistant strains have become common. A vaccine to protect against infection would therefore be beneficial. However, the virulence of S. aureus is determined by a number of different factors, which makes design of a widely effective vaccine difficult. Here, various bacterial virulence factors and attempts to develop vaccines based on these factors are briefly reviewed. In particular, the success of a Phase 3 clinical study of a vaccine directed at capsular polysaccharides types 5 and 8 is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823932     DOI: 10.1016/j.vaccine.2005.01.126

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.

Authors:  Clayton Harro; Robert Betts; Walter Orenstein; Eun-Jeong Kwak; Howard E Greenberg; Matthew T Onorato; Jon Hartzel; Joy Lipka; Mark J DiNubile; Nicholas Kartsonis
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

2.  The potential economic value of a Staphylococcus aureus vaccine for neonates.

Authors:  Bruce Y Lee; Paul J Ufberg; Rachel R Bailey; Ann E Wiringa; Kenneth J Smith; Andrew J Nowalk; Conor Higgins; Angela R Wateska; Robert R Muder
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

3.  Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.

Authors:  Lorena P N Tuchscherr; Fernanda R Buzzola; Lucía P Alvarez; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

4.  Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.

Authors:  Santiago M Lattar; Mariángeles Noto Llana; Philippe Denoël; Sophie Germain; Fernanda R Buzzola; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

Review 5.  Will there ever be a universal Staphylococcus aureus vaccine?

Authors:  Gerald B Pier
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

6.  Safety of Staphylococcus aureus four-antigen and three-antigen vaccines in healthy adults: A meta-analysis of randomized controlled trials.

Authors:  Xiaoqun Xu; Houyong Zhu; Huoyang Lv
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

7.  CD4 T cell antigens from Staphylococcus aureus Newman strain identified following immunization with heat-killed bacteria.

Authors:  Paulraj K Lawrence; Bachra Rokbi; Nadège Arnaud-Barbe; Eric L Sutten; Junzo Norimine; Kevin K Lahmers; Wendy C Brown
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

8.  Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis.

Authors:  Bruce Y Lee; Ann E Wiringa; Rachel R Bailey; G Jonathan Lewis; Jared Feura; Robert R Muder
Journal:  Vaccine       Date:  2010-01-09       Impact factor: 3.641

9.  EsxA might as a virulence factor induce antibodies in patients with Staphylococcus aureus infection.

Authors:  Huiqin Zhou; Hong Du; Haifang Zhang; Haiying Shen; Ruhong Yan; Yun He; Min Wang; Xueming Zhu
Journal:  Braz J Microbiol       Date:  2013-04-09       Impact factor: 2.476

Review 10.  Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.

Authors:  Aisling F Brown; John M Leech; Thomas R Rogers; Rachel M McLoughlin
Journal:  Front Immunol       Date:  2014-01-08       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.